VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
3.250
+0.280 (9.43%)
Dec 26, 2024, 3:39 PM EST - Market open
VYNE Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 0.49 | 0.42 | 0.48 | 0.93 | 20.99 | 0.44 | Upgrade
|
| Revenue | 0.49 | 0.42 | 0.48 | 0.93 | 20.99 | 0.44 | Upgrade
|
| Revenue Growth (YoY) | 39.27% | -11.11% | -48.76% | -95.57% | 4638.83% | -87.68% | Upgrade
|
| Cost of Revenue | - | - | - | - | 1.39 | - | Upgrade
|
| Gross Profit | 0.49 | 0.42 | 0.48 | 0.93 | 19.6 | 0.44 | Upgrade
|
| Selling, General & Admin | 13.91 | 13.38 | 16.39 | 20.3 | 89.54 | 45.11 | Upgrade
|
| Research & Development | 24.29 | 16.31 | 18.39 | 19.54 | 43.53 | 51.2 | Upgrade
|
| Operating Expenses | 38.19 | 29.68 | 34.77 | 39.84 | 133.08 | 96.32 | Upgrade
|
| Operating Income | -37.7 | -29.26 | -34.3 | -38.91 | -113.48 | -95.87 | Upgrade
|
| Interest Expense | - | - | - | -5.61 | -4.39 | -0.92 | Upgrade
|
| Interest & Investment Income | 3.75 | 1.39 | 0.36 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | -0.14 | 0.97 | 1.08 | Upgrade
|
| EBT Excluding Unusual Items | -33.95 | -27.87 | -33.93 | -44.66 | -116.9 | -95.71 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -4.55 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.14 | 0.36 | Upgrade
|
| Other Unusual Items | - | - | - | - | -84.73 | - | Upgrade
|
| Pretax Income | -33.95 | -27.87 | -33.93 | -44.66 | -255.83 | -95.35 | Upgrade
|
| Income Tax Expense | - | - | 0.01 | -0.45 | -0.26 | -0.18 | Upgrade
|
| Earnings From Continuing Operations | -33.95 | -27.87 | -33.95 | -44.21 | -255.57 | -95.18 | Upgrade
|
| Earnings From Discontinued Operations | -0.06 | -0.58 | 10.74 | -29.12 | - | - | Upgrade
|
| Net Income | -34 | -28.45 | -23.21 | -73.33 | -255.57 | -95.18 | Upgrade
|
| Preferred Dividends & Other Adjustments | 0.15 | 0.15 | - | - | - | - | Upgrade
|
| Net Income to Common | -34.15 | -28.6 | -23.21 | -73.33 | -255.57 | -95.18 | Upgrade
|
| Shares Outstanding (Basic) | 40 | 10 | 3 | 3 | 2 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 40 | 10 | 3 | 3 | 2 | 0 | Upgrade
|
| Shares Change (YoY) | 1119.93% | 222.44% | 11.44% | 58.75% | 282.06% | 31.22% | Upgrade
|
| EPS (Basic) | -0.86 | -2.78 | -7.28 | -25.65 | -141.90 | -201.91 | Upgrade
|
| EPS (Diluted) | -0.86 | -2.78 | -7.28 | -25.65 | -141.90 | -201.91 | Upgrade
|
| Free Cash Flow | -30.11 | -25.34 | -29.2 | -56.37 | -137.2 | -74.45 | Upgrade
|
| Free Cash Flow Per Share | -0.76 | -2.47 | -9.17 | -19.72 | -76.18 | -157.94 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 93.37% | 100.00% | Upgrade
|
| Operating Margin | -7646.86% | -6900.47% | -7189.73% | -4179.48% | -540.54% | -21641.76% | Upgrade
|
| Profit Margin | -6926.77% | -6745.52% | -4865.83% | -7876.37% | -1217.40% | -21484.88% | Upgrade
|
| Free Cash Flow Margin | -6107.51% | -5976.65% | -6121.59% | -6054.46% | -653.53% | -16806.32% | Upgrade
|
| EBITDA | - | -29.19 | -34.22 | -38.8 | -113.13 | -95.52 | Upgrade
|
| D&A For EBITDA | - | 0.07 | 0.07 | 0.11 | 0.34 | 0.35 | Upgrade
|
| EBIT | -37.7 | -29.26 | -34.3 | -38.91 | -113.48 | -95.87 | Upgrade
|
| Revenue as Reported | 0.49 | 0.42 | 0.48 | 0.93 | 20.99 | 0.44 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.